Why the Aurora Cannabis (TSX:ACB) UFC Partnership Is a Huge Deal

By partnering with the UFC, Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) has potentially inked a lucrative deal.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

It’s been a tough few months for Aurora Cannabis (TSX:ACB)(NYSE:ACB) investors. After reaching a peak closing price of $13.26 in April, the stock has been on a gradual but noticeable downtrend, following an earnings report that showed high growth but missed analyst expectations. Although the company’s sales jumped 20% quarter over quarter, its net loss was $150 million, showing the company is still a ways off from profitability.

Not all news out of Aurora lately has been bad, however. In addition to growing its sales, the company has been working on acquisitions and partnerships to diversify its product offerings. One of the company’s most interesting partnerships is with the UFC, a mixed-martial-arts (MMA) league whose athletes are well known for endorsing sporting supplements. The deal in question is purported to be a research collaboration, where Aurora and the UFC’s sports performance team will work together to see whether cannabis oil has any benefit to MMA fighters. However, the potential for new performance-enhancing products is not the only benefit that could come from this.

Visibility

One obvious benefit that could come from Aurora’s UFC partnership is visibility. In a crowded market, having a recognizable brand helps you stand out, and if the success of Nike teaches us anything, it’s that hitching yourself to athletics can help with that. Although Aurora’s partnership with the UFC is presently focused on research, it’s possible that a number of branding benefits could come as a result, such as Aurora having its name mentioned on air during UFC shows or branded Aurora products having UFC fighter endorsements.

Research outcomes

Of course, the intended outcome of the Aurora-UFC partnership is to find applications for cannabis oil in sports medicine. Preliminary research has shown that CBD may be cardioprotective, meaning it helps strengthen the heart, and should this be proven conclusively, it would have obvious implications for sports medicine.

Other areas where CBD oil is being researched include depression and anxiety, two conditions that may have a bearing on athletic performance as well. Assuming that Aurora’s research with the UFC sports medicine team is conclusive, it could result in patent-protected products that take off in the world of sports health.

Focus on high-margin product categories

One major benefit of Aurora’s research with the UFC is that it is focused on high-margin products. For cannabis growers, two product areas are most profitable: cannabis oil and pre-rolled joints. By contrast, raw cannabis flower is comparatively cheap and low margin. Since Aurora’s partnership with the UFC is focused on cannabis/CBD oil, any resultant products would be sold in one of the higher-margin cannabis market segments and could prove profitable for Aurora if they take off. This could be a major boon to the company, which is struggling to achieve consistent profits despite soaring revenue.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned. The Motley Fool owns shares of Nike.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »